Inari Medical Enters Into Joint Venture in Greater China

December 6, 2024—Inari Medical, Inc., which is headquartered in Irvine, California, recently announced it has entered into a joint venture with 6 Dimensions Capital and its successor fund 120 Capital, as well as VFLO Medical, a medical device platform incubated by 6 Dimensions and 120 Capital. The venture will provide access to Inari’s venous and other vascular disease technologies for patients in Greater China.

According to Inari, the joint venture will allow the company to commercialize its devices through VFLO’s established infrastructure, local relationships, and commercial expertise in Greater China. VFLO will also have the right to use Inari’s technology to manufacture products for domestic sale in Greater China. VFLO’s expertise and commitment to patients are complementary to Inari’s global strengths in the development, manufacture, and sale of venous thrombectomy and other products, stated the company.

“This joint venture allows many different types of patients and hospitals to access and benefit from Inari’s technologies across multiple segments of China’s complex health care delivery system,” commented Drew Hykes, Chief Executive Officer of Inari, in the press release. “We are excited to partner with 6 Dimensions and 120 Capital to introduce our products through VFLO to the rapidly expanding interventional market in Greater China.”

Rebecca Zhu, Managing Partner of 6 Dimensions Capital and Director of VFLO Medical, added, “Inari is the leader in mechanical thrombectomy, and our strategic partnership is significant and game-changing for the current standard of care in China. We share Inari’s unwavering commitment to developing innovative technologies for underserved patients and believe we can make a meaningful difference in the lives of those suffering from venous and other vascular diseases in China.”